The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

The principal process which terminates the action of
noradrenaline released from adrenergic nerve ending is:
A. Degradation by MAO
B. Methylation by COMT
C. Axonal uptake
D. Extraneuronal uptake
by

1 Answer

Answer :

C. Axonal uptake
by

Related questions

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Description : The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Last Answer : B. Granular uptake

Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Last Answer : Ans: C

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Description : The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Last Answer : B. Granular uptake

At the adrenergic synapse, the concentration of adrenaline in synaptic cleft: a. increased by cocaine which inhibit reuptake of adrenaline b. decreased by MAO (monoamine oxidase) - inhibitors c. controlled chiefly by the activity of the enzyme COMT d. increased by noradrenaline receptor blockers

Description : At the adrenergic synapse, the concentration of adrenaline in synaptic cleft: a. increased by cocaine which inhibit reuptake of adrenaline b. decreased by MAO (monoamine oxidase) - inhibitors c. controlled chiefly by the activity of the enzyme COMT d. increased by noradrenaline receptor blockers

Last Answer : increased by cocaine which inhibit reuptake of adrenaline

The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Description : The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Last Answer : D. All of the above

The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Description : The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Last Answer : D. All of the above

Action of norepinephrine and epinephrine are terminated by (a) Reuptake into nerve terminal (b) Dilution by diffusion and uptake at extraneuronal site (c) Metabolic transformation (d) All of the above

Description : Action of norepinephrine and epinephrine are terminated by (a) Reuptake into nerve terminal (b) Dilution by diffusion and uptake at extraneuronal site (c) Metabolic transformation (d) All of the above

Last Answer : Ans: D

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of acetylcholine released from motor nerve endings to a wider area activating neighbouring receptors C. Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Description : The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of ... Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Last Answer : D. All of the above

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Description : Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Last Answer : C. Slow intravenous infusion

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Description : Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Last Answer : C. Slow intravenous infusion

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Description : Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Last Answer : C. Blocking Na+ channels

Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Description : Tetrodotoxin blocks nerve impulse/junctional transmission by: A. Anticholinergic action B. Depleting acetylcholine C. Blocking Na+ channels D. Blocking Ca2+ channels

Last Answer : C. Blocking Na+ channels

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Description : The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Last Answer : B. Bradycardia

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Last Answer : C. For rapid control of certain symptoms while awaiting response to carbimazole

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates